Impact of Decipher Biopsy testing on clinical outcomes in localized prostate cancer in a prospective statewide collaborative.
Randy A VinceRalph JiangJi QiJeffrey J TosoianRebecca TakeleFelix Y FengSusan LinsellAnna JohnsonSughand ShettyPatrick HurleyDavid C MillerArvin GeorgeKhurshid GhaniFionna SunMariana SeymoreRobert T DessWilliam C JacksonMatthew SchipperDaniel E SprattTodd M MorganPublished in: Prostate cancer and prostatic diseases (2021)
In a prospective statewide registry, high-risk Decipher Biopsy score was strongly and independently associated with conversion from AS to definitive treatment and treatment failure. These real-world data support the clinical utility of Decipher Biopsy. An ongoing phase 3 randomized trial (NCT04396808) will provide level 1 evidence of the clinical impact of Decipher biopsy testing.